Basal-like breast carcinoma

Summary

Basal-like breast carcinoma (MONDO:0004984) is a cancer and 1 clinical trial. Top therapeutic interventions include veliparib. A subtype of invasive ductal breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	basal-like breast carcinoma
Mondo ID	MONDO:0004984
EFO	EFO:0000281
NCIT	C53558
UMLS	C3642347
MedGen	770987
Is cancer (heuristic)	yes

Also known as: basal-like breast cancer · basal-like breast carcinoma · basal-like subtype of breast carcinoma

Disease family

This is a subtype of invasive ductal breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › breast ductal adenocarcinoma › invasive ductal breast carcinoma › basal-like breast carcinoma

Related subtypes (9): breast mucinous carcinoma, breast secretory carcinoma, glycogen-rich clear cell breast carcinoma, acinic cell breast carcinoma, invasive tubular breast carcinoma, scirrhous breast carcinoma, invasive ductal and lobular carcinoma, medullary breast carcinoma, pleomorphic breast carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00892736	PHASE1	COMPLETED	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VELIPARIB	3	2